Adjuvant Post-Tamoxifen Exemestane Trial

Inclusion Criteria

• •postmenopausal women only
• •histologically confirmed stage I-IIIA primary adenocarcinoma of the breast
• •estrogen and/or progesterone receptors positive or unknown
• •patients should have undergone surgery with a curative intent
• •patients must have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day), while tamoxifen could have been discontinued up to 6 months prior to study entry
• •Absence of any evidence of local or distant metastatic disease was required prior to randomization